Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM-001 in Lichen Simplex Chronicus
NCT05454462Phase 1Completed
- Sponsor
- Kamari Pharma
- Start
- May 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KM-001 in lichen simplex chronicus (LSC) (3 arms), sponsored by Kamari Pharma. Primary endpoints: Adverse Events up to 7 weeks, Hematology blood test up to 7 weeks and 9 more. Started May 2022; status: completed.
02
Drugs
KM-001
03
Conditions
lichen simplex chronicus (LSC)
Beyond the preview
Go deeper on NCT05454462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05454462.